NASDAQ$CERS
Cerus Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Cerus reported a revenue increase driven by strong sales of the INTERCEPT Blood System for Platelets in North America and expansion in the U.S., alongside near-complete adoption by Canadian Blood Services.
Cerus Corporation announced financial results for the first quarter ended March 31, 2024, with a 13% increase in total revenue compared to the prior year quarter. Product revenue increased by 24%, driven by strong sales of the INTERCEPT Blood System for Platelets in North America. The company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million.
- Total revenue increased by 13% compared to the prior year quarter.
- Product revenue increased by 24% compared to the prior year quarter.
- U.S. ReCePI Phase 3 clinical trial successfully met primary endpoint for INTERCEPT Blood System for Red Blood Cells.
- The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million.
Headline financials
Revenue & EPS history
Cerus · Revenue · Quarterly
$38.4M
Revenue by segment
Cerus · $47.3M total across 2 segments · Q3 2023
- Product Revenue$39.8M+0.5%84.2%
- Government Contract Revenue$7.48M+10.4%15.8%
Forward guidance
The Company continues to expect full-year 2024 product revenue will be in the range of $172 million to $175 million. Included in this range is full-year 2024 IFC revenue guidance between $8 million to $10 million. The Company expects to report GAAP net loss attributable to Cerus Corporation for the full-year 2024 while also remains committed to adjusted EBITDA breakeven for the full-year 2024.
Tailwinds
- Company expects full-year 2024 product revenue will be in the range of $172 million to $175 million.
- Full-year 2024 IFC revenue guidance between $8 million to $10 million.
- The Company expects to report GAAP net loss attributable to Cerus Corporation for the full-year 2024.
- Company remains committed to adjusted EBITDA breakeven for the full-year 2024.
- Advanced the LED illuminator program towards the Company’s target commercial launch in the EU in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+27.5%
Q3 2017
Best reaction
-19.6%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +34.9% | +58.3% | |
| Q4 2025 | -17.3% | -23.7% | -26.5% | |
| Q3 2025 | -2.8% | +0.0% | +21.4% | |
| Q2 2025 | +0.8% | -2.3% | +3.9% | |
| Q1 2025 | +2.3% | +0.0% | -2.3% | |
| Q4 2024 | -5.2% | -5.7% | -12.1% | |
| Q3 2024 | -7.6% | -8.2% | +8.8% | |
| Q1 2024 | -5.8% | +7.6% | +4.1% | |
| Q4 2023 | +14.2% | +6.6% | -10.8% | |
| Q3 2023 | +25.4% | +25.4% | +21.0% | |
| Q2 2023 | -17.8% | -26.3% | -35.4% | |
| Q1 2023 | -0.9% | -6.1% | -1.7% | |
| Q4 2022 | -7.0% | +2.1% | -1.4% | |
| Q3 2022 | +7.7% | +6.0% | +18.9% | |
| Q2 2022 | -4.5% | -12.7% | -32.8% | |
| Q1 2022 | +2.9% | -2.7% | -2.3% | |
| Q4 2021 | -2.1% | +8.6% | +3.6% | |
| Q3 2021 | +14.5% | +16.0% | +1.5% | |
| Q2 2021 | +21.1% | +21.9% | +28.2% | |
| Q1 2021 | +2.7% | +4.8% | -7.7% | |
| Q4 2020 | -8.6% | -3.9% | -11.3% | |
| Q3 2020 | -5.4% | -0.4% | +18.6% | |
| Q2 2020 | -1.8% | -4.7% | -17.7% | |
| Q1 2020 | +2.1% | +5.2% | +12.5% | |
| Q4 2019 | -1.0% | -6.0% | -39.2% | |
| Q3 2019 | -4.4% | -3.7% | -4.6% | |
| Q2 2019 | -8.7% | -13.5% | -8.2% | |
| Q1 2019 | -12.3% | -15.2% | -27.3% | |
| Q4 2018 | +2.8% | +6.5% | -3.7% | |
| Q3 2018 | -4.9% | -13.4% | -21.6% | |
| Q2 2018 | -5.9% | -4.8% | +4.1% | |
| Q1 2018 | +11.9% | +17.1% | +17.8% | |
| Q4 2017 | +2.1% | +7.5% | +9.0% | |
| Q3 2017 | +27.5% | +26.4% | +40.9% | |
| Q2 2017 | +3.6% | +7.1% | +6.7% | |
| Q1 2017 | -19.6% | -28.3% | -44.5% | |
| Q4 2016 | -7.8% | +5.0% | +0.7% | |
| Q3 2016 | +6.4% | +15.0% | +10.2% | |
| Q2 2016 | +1.8% | -4.5% | -11.3% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +0.5% | — | — | |
| Q3 2015 | +4.5% | — | — | |
| Q2 2015 | -2.5% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | +4.8% | — | — | |
| Q1 2014 | +4.4% | — | — | |
| Q4 2013 | -15.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | +6.7% | — | — | |
| Q1 2013 | -9.7% | — | — | |
| Q4 2012 | +14.0% | — | — | |
| Q3 2012 | -1.9% | — | — | |
| Q2 2012 | -2.7% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2009 | +0.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2010 | -2.8% | — | — | |
| Q2 2011 | -2.8% | — | — | |
| Q4 2010 | -2.8% | — | — | |
| Q1 2010 | -2.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro